Anticoagulant
Anticoagulation Strategies for Blood Clots in Cancer Patients
Recruiting5 awardsPhase 4
Ottawa, Ontario
This trial is for cancer patients who have blood clots and low platelet counts. The investigators will compare two treatment strategies: full dose blood thinners with platelet transfusions or reduced dose blood thinners without transfusions.
Romiplostim for Lymphoma
Recruiting1 awardPhase 2
Miami, Florida
This trial will study whether a drug called romiplostim can help treat low platelet count caused by standard chemotherapy for lymphoma, as well as whether it can prevent the need for chemotherapy dose delays, reductions, or platelet transfusions.
Thrombopoietin Receptor Agonist
Avatrombopag for Pediatric ITP
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing a medication called avatrombopag, which helps increase blood platelets. It targets children who have had low platelet counts for an extended period due to their immune system attacking these cells. The medication works by encouraging the body to make more platelets, which are important for stopping bleeding. Avatrombopag has been shown to increase platelet counts in patients with low platelet levels, including those with liver disease.
Monoclonal Antibodies
Efgartigimod for ITP
Recruiting2 awardsPhase 3
Ocala, Florida
This trial is testing ARGX-113, a medication for adults with primary ITP, a condition where the immune system attacks platelets. The medication aims to calm the immune system to prevent it from attacking these important blood cells.
Bruton's Tyrosine Kinase Inhibitor
Pirtobrutinib for Immune Thrombocytopenic Purpura
Recruiting0 awardsPhase 1 & 2
Washington, District of Columbia
"This trial aims to see how well pirtobrutinib is tolerated and what side effects may occur in patients with Primary Immune Thrombocytopenia. It will also investigate the
Popular Filters
Trials for Thrombocytopenic Purpura Patients
Thrombopoietin Receptor Agonist
Eltrombopag vs Standard Treatment for ITP in Children
Recruiting3 awardsPhase 3
Phoenix, Arizona
This trial tests eltrombopag, a drug that helps make more platelets, in children with a specific blood condition. The goal is to see if it works better than standard treatments.
Monoclonal Antibodies
PF-06835375 for Low Platelet Count
Recruiting1 awardPhase 2
Nyack, New York
This trial uses a new injectable medicine called PF-06835375. It targets adults with long-lasting or chronic low platelet counts due to primary immune thrombocytopenia (ITP). The medicine works by reducing specific immune cells to help increase platelet counts.
Monoclonal Antibodies
Efgartigimod for Low Platelet Count
Recruiting2 awardsPhase 3
Fort Wayne, Indiana
This trial is testing a new injection treatment for adults whose immune systems destroy their own platelets. The treatment aims to calm the immune system to stop it from attacking these important blood cells. Romiplostim promotes platelet production and has been used in the treatment of this condition.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Rilzabrutinib for Immune Thrombocytopenia
Recruiting1 awardPhase 3
Los Angeles, California
This trial tests rilzabrutinib, a drug that may help people with chronic ITP who have very low platelet counts. The drug works by blocking a substance that causes the immune system to destroy platelets. Participants will take the drug for several months to see if it helps increase their platelet levels.
Trials for TTP Patients
Thrombopoietin Receptor Agonist
Eltrombopag vs Standard Treatment for ITP in Children
Recruiting3 awardsPhase 3
Phoenix, Arizona
This trial tests eltrombopag, a drug that helps make more platelets, in children with a specific blood condition. The goal is to see if it works better than standard treatments.
Monoclonal Antibodies
PF-06835375 for Low Platelet Count
Recruiting1 awardPhase 2
Nyack, New York
This trial uses a new injectable medicine called PF-06835375. It targets adults with long-lasting or chronic low platelet counts due to primary immune thrombocytopenia (ITP). The medicine works by reducing specific immune cells to help increase platelet counts.
Monoclonal Antibodies
Efgartigimod for Low Platelet Count
Recruiting2 awardsPhase 3
Fort Wayne, Indiana
This trial is testing a new injection treatment for adults whose immune systems destroy their own platelets. The treatment aims to calm the immune system to stop it from attacking these important blood cells. Romiplostim promotes platelet production and has been used in the treatment of this condition.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Rilzabrutinib for Immune Thrombocytopenia
Recruiting1 awardPhase 3
Los Angeles, California
This trial tests rilzabrutinib, a drug that may help people with chronic ITP who have very low platelet counts. The drug works by blocking a substance that causes the immune system to destroy platelets. Participants will take the drug for several months to see if it helps increase their platelet levels.
Phase 3 Trials
Thrombopoietin Receptor Agonist
Eltrombopag vs Standard Treatment for ITP in Children
Recruiting3 awardsPhase 3
Phoenix, Arizona
This trial tests eltrombopag, a drug that helps make more platelets, in children with a specific blood condition. The goal is to see if it works better than standard treatments.
Romiplostim for Chemotherapy-Induced Low Platelet Count
Recruiting1 awardPhase 3
Jonesboro, Arkansas
This trial tests romiplostim, a drug that boosts platelet production, in adults with certain cancers undergoing chemotherapy. It aims to help these patients maintain their chemotherapy schedule by increasing their platelet counts. Romiplostim has shown effectiveness in increasing platelet counts in patients with low platelet levels due to chemotherapy.
Monoclonal Antibodies
Efgartigimod for Low Platelet Count
Recruiting2 awardsPhase 3
Fort Wayne, Indiana
This trial is testing a new injection treatment for adults whose immune systems destroy their own platelets. The treatment aims to calm the immune system to stop it from attacking these important blood cells. Romiplostim promotes platelet production and has been used in the treatment of this condition.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Rilzabrutinib for Immune Thrombocytopenia
Recruiting1 awardPhase 3
Los Angeles, California
This trial tests rilzabrutinib, a drug that may help people with chronic ITP who have very low platelet counts. The drug works by blocking a substance that causes the immune system to destroy platelets. Participants will take the drug for several months to see if it helps increase their platelet levels.
Trials With No Placebo
Anticoagulant
Apixaban for Blood Clot and Low Platelet Count
Recruiting1 awardPhase < 1
Boston, Massachusetts
This trial aims to test a new dosage of Apixaban for treating cancer patients with blood clots and low platelet counts. Researchers want to see if this treatment is safe and if it reduces bleeding
Platelet Transfusion
Platelet Transfusion Thresholds for Low Platelet Count in Premature Infants
Recruiting1 award1 criteria
Birmingham, Alabama
"This trial aims to see if giving lower amounts of platelet transfusions to very premature babies can help them survive without experiencing severe bleeding up to a certain age."
Procedure
Pulsatile Blood Flow for Reducing Acute Kidney Injury
Recruiting1 award
Aurora, Colorado
This trial aims to see if using a specific type of blood flow during heart surgery can help reduce the risk of kidney damage. Researchers will also look at how safe and effective this method is compared to the
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.